Effect of zanamivir on duration and resolution of influenza symptoms.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Clinical Therapeutics

• Publication date

  2000-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0149-2918(00)83026-XPMID 11117654
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study.

  2000cited by this paper
• Clinical signs and symptoms predicting influenza infection.

  2000cited by this paper
• Zanamivir for the Treatment of Clinically Diagnosed Influenza in Clinical Practice

  2000cited by this paper
• Zanamivir, a New Targeted Therapy in the Treatment of Influenza

  2000cited by this paper
• Zanamivir Susceptibility Monitoring and Characterization of Influenza Virus Clinical Isolates Obtained during Phase II Clinical Efficacy Studies

  2000cited by this paper
• Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors

  2000cited by this paper
• Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections.

  1999cited by this paper
• A novel approach to antiviral therapy for influenza.

  1999cited by this paper
• Zanamivir

  1999cited by this paper
• Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis.

  1999cited by this paper
• Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group.

  1998cited by this paper
• Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

  1997cited by this paper
• Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections

  1997cited by this paper
• Implications of viral resistance to amantadine in control of influenza A.

  1992cited by this paper
• Emergence and apparent transmission of rimantadine-resistant influenza A virus in families.

  1989cited by this paper
• Influenza: quantifying morbidity and mortality.

  1987cited by this paper
• Efficacy of influenza vaccine in nursing homes. Reduction in illness and complications during an influenza A (H3N2) epidemic.

  1985cited by this paper

• Randomized Controlled Trial of Atorvastatin in Acute Influenza in the Emergency Department

  2025cites this paper
• Treatment and prevention of influenza in geriatric patients

  2023cites this paper
• Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial

  2018cites this paper
• A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Virus Monoclonal Antibody, MHAB5553A, in Healthy Volunteers

  2017cites this paper
• Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses

  2017cites this paper
• Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model

  2017cites this paper
• Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A

  2016cites this paper
• Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers

  2016cites this paper
• Antigen-specific H1N1 influenza antibody responses in acute respiratory tract infections and their relation to influenza infection and disease course.

  2014cites this paper
• C-reactive protein as predictor of bacterial infection among patients with an influenza-like illness.

  2013cites this paper
• Influenza testing, diagnosis, and treatment in the emergency department in 2009-2010 and 2010-2011.

  2013cites this paper
• Intravenous Peramivir for Treatment of Influenza A and B Virus Infection in High-Risk Patients

  2011cites this paper
• Estimating Effect of Antiviral Drug Use during Pandemic (H1N1) 2009 Outbreak, United States

  2011cites this paper
• Computational analysis and modeling the effectiveness of 'Zanamivir' targeting neuraminidase protein in pandemic H1N1 strains.

  2011cites this paper
• The use of antiviral agents for the management of severe influenza

  2010cites this paper
• Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation.

  2009cites this paper
• Antivirals and influenza: frequency of resistance.

  2008cites this paper
• Antivirals for the treatment and prevention of epidemic and pandemic influenza

  2007cites this paper
• Vaccines and Antiviral Drugs in Pandemic Preparedness

  2006cites this paper
• A Cost-Benefit Analysis of Testing for Influenza A in High-Risk Adults

  2004cites this paper
• Antiviral drugs in the immunocompetent host: part II. Treatment of influenza and respiratory syncytial virus infections.

  2003cites this paper
• Design and performance testing of quantitative real time PCR assays for influenza A and B viral load measurement

  2003influential citation
• Safety and Efficacy of Nebulized Zanamivir in Hospitalized Patients with Serious Influenza

  2002cites this paper
• Problems of case and disease management in outpatient treatment of influenza

  2002cites this paper
• Influenza vaccines: present and future.

  2002cites this paper
• Zanamivir

  2002influential citation
• Spotlight on Zanamivir in Influenza

  2002cites this paper
• Advances in influenza treatment

  2001cites this paper
• Current research on respiratory viral infections: Fourth International Symposium

  2001cites this paper
• Serum amyloid P component inhibits influenza A virus infections: in vitro and in vivo studies.

  2001cites this paper
• Influenza future: the impact of new vaccines and antivirals

  2001cites this paper